Krystal Biotech Hits New 52-Week High of $355.14, Up 96.83%

Krystal Biotech, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 355.14 on June 18, 2026. This achievement underscores the company's strong performance over the past year, with a remarkable increase of 96.83%, significantly outpacing the S&P 500's growth of 25.41% during the same period. The company's market capitalization stands at USD 7,173 million, reflecting its position within the small-cap segment. Krystal Biotech's price-to-earnings (P/E) ratio is currently at 35.00, indicating investor expectations for future growth. Additionally, the company maintains a return on equity of 16.80%, showcasing its ability to generate profits from shareholders' equity. Despite the absence of dividends, the company's financial health is further illustrated by a debt-to-equity ratio of -0.68, suggesting a strong balance sheet. The price-to-book ratio of 5.88 indicates that the stock is trading at a premium relative to its book value. Overall, Krystal Biotech's recent performance highlights its robust position in the biotechnology landscape.